Alnylam Pharmaceuticals, Inc.

ALNY Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.

231.83 2.20 −0.94%
Market cap
$31.3B
P/E
39.5×
Fwd P/E
39.6×
Dividend yield
—
F-score
6/9
Altman Z
7.30
Beneish M
−1.95
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
7 7 6 6

+8 more TTM periods

ROE
96.55% 90.36% 73.28% 57.72%
ROA
15.30% 11.52% 6.82% 1.70%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
21.16% 15.88% 10.13% 2.65%
Average Days of Receivables
69.35 75.26 76.42 109.70
Free Cash Flow per Share
6.14 4.84 3.55 1.68
Free Cash Flow
819.87 643.34 465.38 221.36
Capital Expenditures
(91.95) (71.56) (58.70) (44.50)
Other line items
Cash ROIC
14.45% 12.63% 9.89% 5.54%
Accounts Receivable Turnover
6.49 6.59 6.28 4.87
Accounts Payable Turnover
9.29 7.34 6.68 5.49
Inventory Turnover
11.58 10.99 8.46 6.83
Average Days of Payables
40.34 56.23 61.94 83.02
Days of Inventory on Hand
36.26 37.31 44.28 53.22
Tax Rate
0.01 (0.02) (0.03) 56.60
Research and Development Expense of Revenue
31.41% 33.11% 35.54% 38.87%
Selling, General and Administrative Expense of Revenue
27.43% 30.17% 32.60% 36.78%
Share Based Compensation of Revenue
7.01% 8.44% 9.38% 11.47%
Interest Coverage
3.52 2.85 1.99 1.30
Operating CF/Net income
1.18 1.33 1.67 3.46
Depreciation/Fixed assets
0.10 0.11 0.11 0.11
Capex/Depreciation
(1.68) (1.31) (1.05) (0.79)
Revenue per Share
35.96 32.26 28.35 24.42
Operating CF per Share
6.82 5.38 4.00 2.02
Capex per Share
(0.69) (0.54) (0.45) (0.34)
Capex to Sales
0.02 0.02 0.02 0.01

Fold the line items

Columns are period end dates